Jennifer R Eads, MD
Associate Professor of Clinical Medicine (Hematology-Oncology)
Department: Medicine
Contact information
Perelman Center for Advanced Medicine
10th Floor South Pavilion
Philadelphia, PA 19104
10th Floor South Pavilion
Philadelphia, PA 19104
Links
Main website for the North American Neuroendocrine Tumor Society
Neuroendocrine Tumor Research Foundation
Main website for the North American Neuroendocrine Tumor Society
Neuroendocrine Tumor Research Foundation
Education:
BS (Genetics )
University of California, Davis , 1999.
MD
Tufts University School of Medicine , 2005.
Permanent linkBS (Genetics )
University of California, Davis , 1999.
MD
Tufts University School of Medicine , 2005.
Description of Clinical Expertise
neuroendocrine tumors and esophagogastric cancerDescription of Research Expertise
neuroendocrine tumors and esophagogastric cancerSelected Publications
Alese OB, Wu C, Chapin WJ, Ulanja MB, Zheng-Lin B, Amankwah M, Eads JR: Update on emerging therapies for advanced colorectal cancer. Am Soc Clin Oncol Edu Book May 2023.Karasic TB, Eads JR, Goyal L: Precision medicine and immunotherapy have arrived for cholangiocarcinoma: an overview of recent approvals and ongoing trials. JCO Precision Oncology April 2023.
Lee H, Nakamoto R, Moore SE, Pantel AR, Eads JR, Aparici CM, Pryma DA: Response to letter to editor re: Combined quantification of 18F-FDG and 68Ga-DOTATATE PET/CT for prognosis in high-grade gastroenteropancreatic neuroendocrine neoplasms. Acad Radiol September 2022.
Lee H, Nakamoto R, Moore SE, Pantel AR, Eads JR, Aparici CM, Pryma DA: Combined quantification of 18F-FDG and 68Ga-DOTATATE PET/CT for prognosis in high-grade gastroenteropancreatic neuroendocrine neoplasms. Acad Radiol September 2022.
Fernandes CJ, Leung G, Eads JR, Katona BW: Gastroenteropancreatic Neuroendocrine Tumors. Gastroenterol Clin North Am September 2022.
Tarhini AA, Eads JR, Moore KN, Tatard-Leitman V, Wright JJ, Forde PM, Ferris RL: Neoadjuvant immunotherapy of locoregionally advanced solid tumors. J Immunother Cancer August 2022.
Chapin WJ, Till JE, Hwang W-T, Eads JR, Karasic TB, O'Dwyer PJ, Schneider CJ, Teitelbaum UR, Romeo J, Black TA, Christensen TE, Redlinger Tabery C, Anderson A, Slade M, LaRiviere M, Yee SS, Reiss Binder KA, O'Hara MH, Carpenter EL: Multi-analyte prognostic signature including circulating tumor DNA and circulating tumor cells in patients with advanced pancreatic adenocarcinoma. JCO Precision Oncology July 2022.
Eads JR, Catalano PJ, Fisher GA, Rubin D, Iagaru A, Klimstra D, Konda B, Kwong MS, Chan JA, De Jesus-Acosta A, Halfdanarson TR, Shaib WL, Soares HP, Hong SC, Wong TZ, O'Dwyer PJ: Randomized phase II study of platinum and etoposide versus temozolomide and capecitabine in patients with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms: ECOG-ACRIN EA2142. American Society of Clinical Oncology Annual Meeting, Chicago, IL Jun 2022 Notes: "Oral Presentation"
Lau-Min KS, Li Y, Eads JR, Mamtani R, Getz KD: Association between timely targeted treatment and outcomes in patients with metastatic Her2-overexpressing gastroesophageal adenocarcinoma. Cancer 128(9): 1853-1862, May 2022.
Eads JR: Is it time yet for adjuvant immunotherapy for patients with DNA mismatch repair deficient gastric cancer? Ann Surg Oncol 29(4): 2141-2143, Apr 2022.